Breast Cancer Treatment and Side Effects
CDK 4/6 inhibitors for early breast cancer: Q&A with Dr. Kelly McCann
As CDK 4/6 inhibitors become more widely used in early-stage breast cancer, an important question remains: who truly benefits from these therapies? At the San Antonio Breast Cancer Symposium (SABCS), researchers shared updates on how care teams can better personalize treatment decisions with new data. We asked UCLA Health breast oncologist Dr. Kelly McCann to […]











